CD274 and carcinoma: This is because PD‐L1 has been widely used as a marker to predict the therapeutic efficacy of ICI, but the effects of ICI are known to be weak when tumor‐infiltrating T lymphocytes are relatively scarce, despite high levels of PD‐L1 in carcinoma cells.37, 38